A recent study found that rosiglitazone may inhibit breast cancer growth in mice by suppressing the expression of a pro-inflammatory and pro-tumor protein Gpr132 in tumor-associated macrophages [4]. This evidence concerns the gene GPR132 and breast carcinoma.